Effect of neonatal exposure to the antioestrogens nafoxidine and CI-628 upon the development of the uterus in the prepubertal rat.
Neonatal Sprague-Dawley rats were injected with the antioestrogens nafoxidine or CI-628 on Day 3 of life alone or in combination with oestradiol benzoate 24 h later. Oestrogen-stimulated glucose oxidation and cytoplasmic oestrogen binding sites of the uteri were assessed at 21-23 days of age. Neither antioestrogen antagonized the prepubertal uterine impairments produced by neonatal oestradiol treatment. Both antioestrogens administered alone produced deficits which mimicked those produced by neonatal oestrogenization. However, the agonist property of each antioestrogen was differentially expressed: treatment with CI-628 reduced prepubertal oestrogen binding sites in the uterus, but nafoxidine exposure decreased the sensitivity of the uterus to oestradiol stimulation of glucose oxidation. It is postulated that CI-628 directly affects the uterus to reduce production of oestrogen receptor protein, while nafoxidine affects the development of the uterine phosphogluconate oxidative pathway indirectly through impaired ovarian function. However, antioestrogens blocked the neonatal oestradiol-induced reduction in the oestrogen-stimulated production of actomyosin in the adult uterus. Therefore, while both CI-628 and nafoxidine are clearly agonists in the neonatal rat, each appears to exhibit cell-specific agonist and antagonist properties.
Campbell
P S
PS
Department of Biological Sciences, University of Alabama in Huntsville 35899.
Satterfield
P M
PM
D000205:Actomyosin / Q000378:metabolism; D000818:Animals; D003593:Cytoplasm / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D005947:Glucose / Q000378:metabolism; D009256:Nafoxidine / Q000494:pharmacology*; D010052:Ovariectomy; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011960:Receptors, Estrogen / Q000378:metabolism; D012741:Sexual Maturation; D013267:Stilbenes / Q000494:pharmacology*; D014599:Uterus / Q000187:drug effects / Q000254:growth & development* / Q000378:metabolism
D011759:Pyrrolidines; D011960:Receptors, Estrogen; D013267:Stilbenes; D009256:Nafoxidine; D004958:Estradiol; C029102:CI 628M; D000205:Actomyosin; D005947:Glucose